Scott Harris

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.

Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA.

Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA.

LAV Management Co., Ltd. (LAV) is a venture capital subsidiary of Eli Lilly & Co. founded in 2008. The firm is headquartered in Shanghai, China with branches located in Central, Hong Kong and California, United States.

Beijing PINS Medical Co., Ltd. is a medical company based in Beijing, China. The Chinese company's main focus is on pinch medical. The company was founded in 2008. The CEO is Hongwei Hao.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA.

Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021.

Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang.

Avistone Pharmaceuticals is a Chinese clinical-stage biotechnology company that specializes in precision oncology therapeutics. The company is located in China.

Visirna Therapeutics, Inc. manufactures and commercializes RNAi-based investigational cardiometabolic medicines. The company is based in Shanghai, China.

Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19.

RiboX Therapeutics, Inc. engages in the development of fully engineered circular RNA therapeutics. The private company is based in Shanghai, China.

Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies.

Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China.

Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.

Gwynant Therapeutics develops new small molecules for oncology targets.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation.

MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN.

Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.

Part of Frontera Therapeutics, Inc., Frontera Therapeutics (HK) Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company was founded by Yong Dai and Yong Dai has been the CEO since incorporation.

Echosens SA engages in the manufacture of medical imaging equipment. It focuses on developing FibroScan. The company was founded by Laurent Sandrin and Sylvain Yon on June 20, 2001 and is headquartered in Paris, France.

Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters.

The New York City Investment Fund Manager Inc. (The New York City Investment Fund Manager) is a venture capital firm founded by Henry Kravis in 1996. The firm is headquartered in New York, United States.

Rubedo Life Sciences, Inc. develops intelligent drug platform to design unique, targeted and controlled therapies for age-related diseases. The company was founded by Marco Quarta, Mark Gallop and Julian Klein in 2018 and is headquartered in Silicon Valley, CA.

Piper Sandler & Co. (Broker) (PSC-Broker) is the full-service brokerage division of Piper Sandler & Co., a financial service firm headquartered in Minneapolis, Minnesota. They are a subsidiary of Piper Sandler Companies (NYSE: PIPR). The firm was founded in 1969 and previously known as Piper Jaffray & Co. They became Piper Sandler & Co. when Piper Jaffray Companies and Sandler O’Neill & Partners, L.P. merged to become Piper Sandler Companies in 2020. PSC-Broker provides brokerage and investment banking services to financial institutions, corporations and other financial investors. Their core focus sectors are Agriculture, renewables & cannabis, Business services, Chemicals & Materials, Consumer, Diversified industrials & services, Energy, Financial services, financial sponsors, Healthcare, and Technology.